Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter blood thinner course after delivery may be safe for some women

NCT ID NCT07342127

Prevention Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 86 women with Factor V Leiden or Factor II mutations who had no history of blood clots. Researchers compared how long doctors prescribed blood thinners after childbirth (less than 2 weeks vs. 6 weeks) to see if shorter treatment was still effective at preventing dangerous clots. The goal was to find the best balance between preventing clots and avoiding side effects from medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

86 people

The number who actually took part.

Started

Feb 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female patients over than 18 years old, carrying asymptomatic heterozygous Factor V Leiden or Factor II mutation ; who consulted in Hospices Civils de Lyon for this condition, and who delivered between 01/01/2020 and 31/12/2026.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 * Heterozygous asymptomatic Factor V Leiden mutation or Factor II mutation, diagnosed before or during pregnancy * Delivering between 01/01/2020 and 31/12/2025 * Patient with French social security rights Exclusion Criteria: * NA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Factor ii heterozygous mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

puerperal disorder thrombophilia thrombophilia due to activated protein C resistance venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Factor ii heterozygous mutation Factor V leiden heterozygous mutation Postpartum Pregnancy

Contacts and locations

Locations

  • Service Gynécologie Obstétrique - Hôpital de la Croix Rousse

    Lyon, 69004, France

  • Service d'hémostase clinique - Hôpital Louis Pradel

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.